MDRNA Acquires Dx Rights to UNA Tech in Bid to Move Beyond siRNA Drugs

"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.